Pfizer PFE faces patent expirations amounting to more than one quarter of 2024 revenue by 2028, and the 2023 acquisition of oncology-focused biotech Seagen boosted the firm’s invested capital base, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback